Is Melanotan Nasal Spray Safer? Neither Route Has Been Tested

Nasal tanning sprays and melanotan injections contain the same peptide, and no safety study has been run on either route.¹² Skipping the needle removes one specific risk and leaves every other one in place, so the nasal version reads gentler than it is.

There is one documented melanoma linked specifically to the spray form, and it did not appear on skin.³

What is in a tanning nasal spray?

Melanotan II is the active peptide in the sprays sold for tanning. A 2024 paper in Cutis describes it plainly: "The active ingredient in the tanning spray is melanotan II," and identifies the molecule as "a synthetic analog of α‒melanocyte-stimulating hormone."⁴

Alpha-MSH is the signal your body already uses to tell pigment cells to make melanin. Synthetic analogs bind the same receptors, so the tanning effect is real and the mechanism is not mysterious. Everything uncertain about these products sits elsewhere.

A Norwegian risk profile on both melanotan compounds notes that what reaches buyers is not a characterized product: "Illegal melanotan products for subcutaneous self-injection or nasal spray are proliferating on the internet."² Cancer Research UK puts the same point in consumer terms, saying "Melanotan products have not been tested for safety, quality or effectiveness" and that they "could have harmful chemicals in them that aren't listed on the label."¹

Is melanotan the same thing as the approved tanning drug?

Afamelanotide and melanotan II are different molecules with different legal standing. Afamelanotide, sold as Scenesse, holds FDA approval. Melanotan II holds none, and the Cutis authors state it directly: "Melanotan II is not approved by the US Food and Drug Administration."⁴

Approval does not extend to cosmetic tanning. Its indication is narrow, covering adults with a rare light-sensitivity disorder, and the label describes the purpose as to "increase pain free light exposure in adult patients with a history of phototoxic reactions" from erythropoietic protoporphyria.⁵

Afamelanotide's sequence appears on the label as "Ac-Ser-Tyr-Ser-Nle-Glu-His-(D)Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2," with a molecular weight of "1646.85 (anhydrous free base)."⁵ Melanotan II is a shorter cyclic peptide and a separate compound. Treating a finding about one as a finding about the other does not hold up, in either direction.

How does the approved drug reach the body?

Scenesse goes under the skin as an implant, placed by a trained clinician. On the label, placement is specified: "Insert a single SCENESSE implant (containing 16 mg of afamelanotide) subcutaneously above the anterior supra-iliac crest," every two months.⁵

No approved melanocortin agonist is delivered as a nasal spray. Only one product has cleared a regulatory review for this receptor family, and it uses a route nobody can perform on themselves, at a frequency a clinic controls, with the dose fixed in the device.

Does melanotan absorb through the nose?

Nobody has established absorption by any route other than injection. The Norwegian risk profile is blunt about it: "Currently the only efficient administration is sub cutaneous injection."² That document carries a version date of 17 February 2012, so it is old, and no newer regulatory assessment of nasal absorption has replaced it.

Beyond absorption, that profile lists what is known about how the compound behaves once it is in the body. The profile records distribution, metabolism and excretion each as "No data retrieved."² For skin, it reports that "Transdermal penetration of MT-I through mammalian skin seems to be rather inefficient," giving a figure below 0.05% in intact rodent skin.²

Here the intuition runs backwards. An inefficient route is not a gentler route. If a spray delivers an uncertain fraction of what a needle delivers, the person using it adjusts by using more, and nobody involved knows what fraction they are adjusting from.

What happened in the one nasal spray melanoma case?

A 2026 case report in Life describes a patient who "had been using a Melanotan II nasal spray prior to UV tanning sessions" and who developed a melanoma in the mouth.³ The author calls that case "believed to be the first documented instance of oral mucosal melanoma linked to the nasal spray form of Melanotan II."³

By the time it was found, the tumor was advanced. Histopathology is reported as a "pT4 melanoma infiltrating the alveolar bone, with a depth of invasion measuring 9 mm."³

That description reaches this page through a reproduction. Bonchev is reporting a different team's case, and the original could not be opened from here, so what appears above is the 2026 paper's account of it and not the primary.³ One case also establishes a sequence of events and not a cause.

What does the injected route show in the case literature?

Pigment changes and new moles recur across the injection case reports. A 2020 report describes a patient after "a four week period of self-injecting MT II" who developed "a 0.8 by 0.6 mm brown macule" at the jaw angle, with "melanoma in-situ, Clark and Breslow level 1" confirmed on biopsy.⁶

A 2024 case series describes a patient who was "applying Melanotan nasal spray and injecting herself" daily for six months, and who developed new irregular moles found to be mildly dysplastic.⁷ That patient used both routes at once, so it tells you nothing about which one mattered.

The Cutis authors summarize the broader picture as "Several case reports have linked melanotan II to cutaneous changes," naming dysplastic nevi and melanoma, and add that "Less common complications, such as renal infarction and priapism, also have been observed."⁴ Their reference list did not render on the page read for this guide, so the specific reports behind those two sentences stayed unverified.

Is there proof melanotan causes melanoma?

No, and the sources that are most critical of these products say so themselves. The Norwegian profile states that "there is still no clear relationship between the development of melanoma and the use of melanotan," and separately that "the association between melanotan and malignant melanoma is not scientifically documented."² The 2026 case report agrees: "conclusive evidence confirming a direct causal relationship remains lacking."³

Holding that line matters, because the skeptical case is weaker than the headlines suggest. The literature on this question consists of case reports and a plausible mechanism, and both the Norwegian profile and the 2026 case report describe the melanoma association as undocumented.²³

The Norwegian document states the concern in its own words without overstating it: "there is concern that long term use might lead to increased risk for malignant melanoma," and it describes the signal clinicians are told to watch for as "increased size and darkening of naevi."²

What does the approved label say about watching your skin?

Scenesse's label recommends routine whole-body skin surveillance for everyone taking it. Section 5.1 reads: "A full body skin examination (twice yearly) is recommended to monitor pre-existing and new skin pigmentary lesions."⁵

Pigment lesions also show up in the trial safety data. Across 125 patients on Scenesse against 119 on vehicle, melanocytic nevus was reported in 4% against 2%, and skin hyperpigmentation in 4% against 0%.⁵

Those numbers are small, and they come from a drug that went through a controlled program with a defined dose and a clinician placing it. Twice-yearly exams attach to that version of the drug. Nobody has written a monitoring schedule for a spray of unknown concentration.

Does the US treat sprays differently from injections?

Melanotan II has no approved status in the US in any form, so the spray and the needle sit in the same regulatory position.⁴ People assume a split where a spray counts as a cosmetic and an injection counts as a drug, and that split does not follow from how the compound is classified.

Does the UK treat sprays differently?

UK rules are explicit about injections and silent about sprays. Cancer Research UK states that "It is illegal to sell and supply Melanotan injections in the UK," citing a 2008 MHRA position that a tan jab "is an unlicensed medicine and may not be safe."¹

That page says nothing about the legal status of the spray. It does give advice on it, saying "Melanotan nasal sprays are not safe and shouldn't be used" and that "Melanotan nasal sprays and injections are not safe to use."¹ A UK trading standards leaflet describes melanotan 2 as "not regulated for use in sprays" and warns that the sprays "can also contain contaminants."⁸

An explicit ban on one route sitting beside no stated rule for the other is probably part of why the spray reads as the softer option. A quieter legal record is not a cleaner safety record.

Why does the nasal route feel like the cautious choice?

Skipping a needle removes needle risks, and those are real. Blood-borne virus exposure is named in the Norwegian profile as a concern tied to self-injection, and Cancer Research UK tells people who have used melanotan to "Talk to your GP if you have shared needles with someone."¹² Somebody choosing a spray to avoid that is reasoning correctly about that specific hazard.

Where the reasoning breaks is in what the choice is assumed to cover. Shared-needle risk comes from the needle. Receptor effects, pigment changes, product contamination and unknown dose all come from the compound and from whoever made it, and a spray changes none of them.¹⁸

What does the nasal route expose that an injection does not?

Nasal delivery puts the compound across mucosa, and injection does not. Sprayed into the nose, the compound drains to the nasopharynx and the mouth, so the tissue lining those surfaces takes a local exposure that a subcutaneous injection in the abdomen never produces.

Oral mucosa responds to this compound. The 2026 report describes an injecting patient, not a spray user, who developed "brown pigmentation of the attached gingiva in both the maxillary and mandibular arches," with "Additional pigmented areas" on both cheeks, while "the tongue, palatal mucosa, and lips showed no signs of pigmentation."³ Those changes faded after stopping, with buccal pigmentation nearly gone and gingival pigmentation still present at three months.³

Mucosal pigment change therefore happens even by the systemic route, and the single reported melanoma tied specifically to the spray appeared in mucosa.³ That is a thin evidence base. It points at a tissue the needle route does not reach directly, and it is the opposite of the reassurance the spray is chosen for.

What has not been measured?

Four gaps sit under this whole question, and each is specific.

Nasal bioavailability has no published figure, so a dose in a spray bottle has no known relationship to a dose in a syringe.² Distribution, metabolism and excretion were recorded as having no data retrieved, so how long the compound stays and where it goes is open.² No cohort study has followed melanotan users for melanoma outcomes, and that absence is why the regulators and the case authors both decline to claim causation.²³ And product contents vary by seller, so consistency between two bottles is unestablished.¹⁸

A fifth gap belongs to this page and not to the compound. Label copy cited here came from an FDA document that states it "may not be the latest approved by FDA," so the Scenesse figures should be checked against current labeling before anyone relies on them.⁵

Common questions

Is melanotan nasal spray approved anywhere?

Is nasal melanotan safer than injecting it?

How much melanotan does a nasal spray deliver?

Is there an FDA-approved melanocortin drug?

Is Scenesse a tanning drug?

Does melanotan cause melanoma?

Has any melanoma been reported after nasal spray use?

Why would a tanning spray cause a melanoma in the mouth?

Do moles change on melanotan?

What does the approved drug's label say about mole monitoring?

Did pigment lesions show up in the approved drug's trials?

Are melanotan injections legal in the UK?

Are nasal sprays legal in the UK?

What else has been reported with melanotan II?

Can you tell if somebody is using melanotan?

Does the pigmentation reverse after stopping?

Sources

1. Cancer Research UK. "Fake tan and Melanotan." Last reviewed 30 November 2023, next review due 30 November 2026. Read at source. Quotes the MHRA's 2008 position that a "tan jab" is an unlicensed medicine. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10
2. Risk Profile Melanotan I and Melanotan II. Version dated 17 February 2012, with a reporting date of 15 January 2013, hosted by the Norwegian Food Safety Authority (Mattilsynet). Read at source. The document does not name its authoring body in the text, so it is cited here as a regulator-hosted risk profile and not as an attributed agency opinion. It is also fourteen years old, and no newer regulatory assessment of nasal absorption was found. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17
3. Bonchev A. "Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report." Life 2026;16(2):265. DOI 10.3390/life16020265. Read at source. The oral mucosal melanoma case attributed to Alsabbagh et al. is reported via this paper's account of it; the original report could not be reached from this environment, so that case is sourced one step removed. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15
4. Newton J, Reinschmidt A, Van Gorp R, Sonstegard A. "Nasal Tanning Sprays: Illuminating the Risks of a Popular TikTok Trend." Cutis 2024 Jan;113(1):E3-E4. DOI 10.12788/cutis.0933. Read at the publisher's platform. The article's reference list did not render, so the case reports it summarizes remain unverified at their own sources. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6
5. Clinuvel Pharmaceuticals. SCENESSE (afamelanotide) implant, for subcutaneous use. US prescribing information. Read at source from the FDA label PDF on accessdata.fda.gov. The document states that this copy "may not be the latest approved by FDA." ↩1 ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12
6. Mallalieu JE. "Melanoma In-Situ Associated with Melanotan II Use." Journal of Case Reports: Clinical & Medical 2020;3(1):147. Read at source. A single case report in a low-circulation journal with no DOI shown, so it carries less weight than the peer-reviewed sources above. ↩1
7. Al Abadie M, Sharara Z, Puthan Veetil J. "Tanning Melanotan Jabs and Nasal Spray: Safe or Not?" Medical & Clinical Research 2024;9(2):01-08. ISSN 2577-8005. Read at source via an institutional repository copy. No DOI is shown on the article, and the journal is not indexed in the major databases, so it ranks as the weakest of the peer-reviewed citations here. ↩1 ↩2
8. Chartered Trading Standards Institute. "Nasal tanning" consumer leaflet, hosted by Lancashire County Council. Read at source. No publication date appears on the document, so its currency is unestablished. ↩1 ↩2 ↩3 ↩4